Dorit Reiss

Dorit Reiss is not mentioned in the provided news articles. The articles focus on the FDA's decision to decline reviewing Moderna's application for a new flu vaccine. The decision is described as unexpected, given the FDA's prior approval of the project, and is attributed by some experts to an 'anti-vaccine agenda' within the Trump administration. The FDA's refusal to consider the application, based on concerns about Moderna's clinical trial results, is seen as potentially impacting the development and approval process for other new and updated vaccines in the US. The articles highlight the controversy surrounding the decision and its potential implications for public health and vaccine innovation.